These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 7904509)
1. Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis. Jorge LF; Arias TD; Griese U; Nebert DW; Eichelbaum M Pharmacogenetics; 1993 Oct; 3(5):231-8. PubMed ID: 7904509 [TBL] [Abstract][Full Text] [Related]
2. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama. Petersen DD; Kong AN; Jorge LF; Nebert DW; Arias TD Pharmacogenetics; 1991 Dec; 1(3):136-42. PubMed ID: 1688244 [TBL] [Abstract][Full Text] [Related]
3. Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations. Jorge LF; Eichelbaum M; Griese EU; Inaba T; Arias TD Pharmacogenetics; 1999 Apr; 9(2):217-28. PubMed ID: 10376769 [TBL] [Abstract][Full Text] [Related]
4. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947 [TBL] [Abstract][Full Text] [Related]
5. [Human biodiversity and its effects on the pharmacological variability: CYP2D6 and NAT2 enzymes in Amerind populations of Panama, Colombia and Costa Rica]. Jorge LF; Arias TD Rev Med Panama; 1995 Sep; 20(3):98-107. PubMed ID: 8668827 [TBL] [Abstract][Full Text] [Related]
6. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816 [TBL] [Abstract][Full Text] [Related]
7. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Dahl ML; Yue QY; Roh HK; Johansson I; Säwe J; Sjöqvist F; Bertilsson L Pharmacogenetics; 1995 Jun; 5(3):159-64. PubMed ID: 7550367 [TBL] [Abstract][Full Text] [Related]
8. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268 [TBL] [Abstract][Full Text] [Related]
10. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258 [TBL] [Abstract][Full Text] [Related]
11. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population. Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247 [TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Masimirembwa CM; Johansson I; Hasler JA; Ingelman-Sundberg M Pharmacogenetics; 1993 Dec; 3(6):275-80. PubMed ID: 7908586 [TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6. Heim MH; Meyer UA Methods Enzymol; 1991; 206():173-83. PubMed ID: 1686063 [No Abstract] [Full Text] [Related]
14. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Kimura S; Umeno M; Skoda RC; Meyer UA; Gonzalez FJ Am J Hum Genet; 1989 Dec; 45(6):889-904. PubMed ID: 2574001 [TBL] [Abstract][Full Text] [Related]
15. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients. Roots I; Brockmöller J; Drakoulis N; Loddenkemper R Clin Investig; 1992; 70(3-4):307-19. PubMed ID: 1355678 [TBL] [Abstract][Full Text] [Related]
16. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439 [TBL] [Abstract][Full Text] [Related]
17. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Armstrong M; Daly AK; Cholerton S; Bateman DN; Idle JR Lancet; 1992 Apr; 339(8800):1017-8. PubMed ID: 1349052 [TBL] [Abstract][Full Text] [Related]
18. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls. Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046 [TBL] [Abstract][Full Text] [Related]
19. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380 [TBL] [Abstract][Full Text] [Related]
20. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Daly AK; Fairbrother KS; Andreassen OA; London SJ; Idle JR; Steen VM Pharmacogenetics; 1996 Aug; 6(4):319-28. PubMed ID: 8873218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]